

Patrizia Bagnarelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/111039/publications.pdf>

Version: 2024-02-01

74
papers

2,168
citations

257429

24
h-index

254170

43
g-index

74
all docs

74
docs citations

74
times ranked

2366
citing authors

#	ARTICLE	IF	CITATIONS
1	Visceral fat inflammation and fat embolism are associated with lung's lipidic hyaline membranes in subjects with COVID-19. <i>International Journal of Obesity</i> , 2022, 46, 1009-1017.	3.4	22
2	Synergistic effect of antimicrobial peptide LL-37 and colistin combination against multidrug-resistant <i>Escherichia coli</i> isolates. <i>Future Microbiology</i> , 2021, 16, 221-227.	2.0	12
3	ANCA-Associated Glomerulonephritis and Anti-Phospholipid Syndrome in a Patient with SARS-CoV-2 Infection: Just a Coincidence?. <i>Case Reports in Nephrology and Dialysis</i> , 2021, 11, 214-220.	0.6	12
4	Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation. <i>Vaccines</i> , 2021, 9, 1124.	4.4	3
5	Quantification of the HIV-1 total reservoir in the peripheral blood of naïve and treated patients by a standardised method derived from a commercial HIV-1 RNA quantification assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 609-617.	2.3	1
6	Locally acquired hepatitis E virus in Marche Italy: Clinical/laboratory features and outcome. <i>Digestive and Liver Disease</i> , 2020, 52, 434-439.	0.9	4
7	Evaluation of the Ion AmpliSeq SARS-CoV-2 Research Panel by Massive Parallel Sequencing. <i>Genes</i> , 2020, 11, 929.	2.4	27
8	Antimicrobial Resistance: A Challenge for the Future. , 2020, , 13-29.		3
9	Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1443-1446.	6.0	8
10	Local Epidemics Gone Viral: Evolution and Diffusion of the Italian HIV-1 Recombinant Form CRF60_BC. <i>Frontiers in Microbiology</i> , 2019, 10, 769.	3.5	6
11	Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 515-519.	2.5	26
12	Molecular Characterization of Italian Isolates of Fluoroquinolone-Resistant <i>Streptococcus agalactiae</i> and Relationships with Chloramphenicol Resistance. <i>Microbial Drug Resistance</i> , 2018, 24, 225-231.	2.0	12
13	Hepatitis E in Italy: 5 years of national epidemiological, virological and environmental surveillance, 2012 to 2016. <i>Eurosurveillance</i> , 2018, 23, .	7.0	28
14	HIV avidity index performance using a modified fourth-generation immunoassay to detect recent HIV infections. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 2010-2019.	2.3	6
15	HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users. <i>PLoS ONE</i> , 2016, 11, e0146097.	2.5	25
16	Hepatitis E in a region of Italy: An emerging autochthonous infection?. <i>Digestive and Liver Disease</i> , 2016, 48, 1340-1345.	0.9	11
17	Chronic hepatitis E in a patient treated with rituximab and mycophenolate mofetil for Sjögren's syndrome. <i>Rheumatology</i> , 2016, 55, 2275-2277.	1.9	18
18	Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics. <i>Journal of Medical Virology</i> , 2014, 86, 729-736.	5.0	29

#	ARTICLE	IF	CITATIONS
19	HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes. BMC Infectious Diseases, 2014, 14, 222.	2.9	28
20	Heterogeneity of West Nile virus genotype 1a in Italy, 2011. Journal of General Virology, 2013, 94, 314-317.	2.9	5
21	Human Arthropod-Borne Viral Infections. BioMed Research International, 2013, 2013, 1-2.	1.9	3
22	High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype. Journal of Antimicrobial Chemotherapy, 2012, 67, 1250-1253.	3.0	7
23	Characterization of a Streptococcus suis tet(O/W/32/O)-Carrying Element Transferable to Major Streptococcal Pathogens. Antimicrobial Agents and Chemotherapy, 2012, 56, 4697-4702.	3.2	62
24	HIV-1 Subtype F1 Epidemiological Networks among Italian Heterosexual Males Are Associated with Introduction Events from South America. PLoS ONE, 2012, 7, e42223.	2.5	22
25	Hepatitis C virus core antigen: Analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. Journal of Clinical Virology, 2011, 51, 264-269.	3.1	81
26	Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. BMC Infectious Diseases, 2011, 11, 310.	2.9	21
27	A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen. BMC Medical Informatics and Decision Making, 2011, 11, 40.	3.0	7
28	Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice. Journal of Medical Virology, 2010, 82, 1996-2003.	5.0	6
29	Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. Retrovirology, 2009, 6, 4.	2.0	18
30	Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. BMC Microbiology, 2008, 8, 112.	3.3	21
31	Anti-HIV-1 Response Elicited in Rabbits by Anti-Idiotypic Monoclonal Antibodies Mimicking the CD4-Binding Site. PLoS ONE, 2008, 3, e3423.	2.5	21
32	Human papillomavirus infections: new perspectives for prevention and treatment. New Microbiologica, 2007, 30, 189-212.	0.1	6
33	Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment. Antimicrobial Agents and Chemotherapy, 2004, 48, 3253-3259.	3.2	83
34	Genotypic and Phenotypic Correlates of the HIV Type 1 env Gene Evolution in Infected Children with Discordant Response to Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 1306-1313.	1.1	14
35	Analysis of the functional relationship between V3 loop and gp120 context with regard to human immunodeficiency virus coreceptor usage using naturally selected sequences and different viral backbones. Virology, 2003, 307, 328-340.	2.4	16
36	Molecular analysis of Tn1546-like elements mediating high-level vancomycin resistance in Enterococcus gallinarum. Journal of Antimicrobial Chemotherapy, 2003, 52, 772-775.	3.0	14

#	ARTICLE	IF	CITATIONS
37	Processivity and drug-dependence of HIV-1 protease. <i>Aids</i> , 2003, 17, 663-671.	2.2	31
38	Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. <i>Aids</i> , 2003, 17, 663-71.	2.2	9
39	Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. <i>Journal of Medical Virology</i> , 2002, 68, 479-488.	5.0	90
40	Inhibition of HIV-1 Tat Activity Correlates with Down-Regulation of bcl-2 and Results in Reduction of Angiogenesis and Oncogenicity. <i>Virology</i> , 2002, 299, 1-7.	2.4	12
41	Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy. <i>Aids</i> , 2000, 14, 1101-1110.	2.2	13
42	Identification of Two Distinct Subsets of Long-Term Nonprogressors with Divergent Viral Activity by Stromal-Derived Factor 1 Chemokine Gene Polymorphism Analysis. <i>Journal of Infectious Diseases</i> , 1999, 180, 285-289.	4.0	29
43	Defective nef Alleles in a Cohort of Hemophiliacs with Progressing and Nonprogressing HIV-1 Infection. <i>Virology</i> , 1999, 259, 349-368.	2.4	53
44	Host-Specific Modulation of the Selective Constraints Driving Human Immunodeficiency Virus Type 1 <i>env</i> Gene Evolution. <i>Journal of Virology</i> , 1999, 73, 3764-3777.	3.4	34
45	A Combination of Nucleoside Analogues and a Protease Inhibitor Reduces HIV-1 RNA Levels in Semen: Implications for Sexual Transmission of HIV Infection. <i>Antiviral Therapy</i> , 1999, 4, 95-99.	1.0	12
46	Rare mutations in a domain crucial for V3-loop structure prevail in replicating HIV from long-term non-progressors. <i>Aids</i> , 1998, 12, 985-997.	2.2	27
47	Dynamic Features of Human Immunodeficiency Virus Type 1 (HIV-1) Viremia: Kinetics of Cell-Free HIV-1 RNA after Therapeutic Plasma Exchange. <i>Journal of Infectious Diseases</i> , 1997, 176, 801-804.	4.0	10
48	Changes in CD8 Cell Subpopulations Induced by Antiretroviral Therapy in Human Immunodeficiency Virus Infected Patients. <i>Viral Immunology</i> , 1997, 10, 207-212.	1.3	21
49	Comparable Biological and Molecular Determinants in HIV Type 1-Infected Long-Term Nonprogressors and Recently Infected Individuals. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 337-341.	1.1	19
50	Homozygous $\Delta 32$ deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. <i>Aids</i> , 1997, 11, F67-F71.	2.2	108
51	Patterns of In Vitro Anti-Human Immunodeficiency Virus Type 1 Antibody Production in Long-Term Nonprogressors. <i>Clinical Immunology and Immunopathology</i> , 1997, 85, 320-323.	2.0	4
52	Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. <i>Aids</i> , 1996, 10, F51-F56.	2.2	143
53	Quantitative molecular methods in virology. <i>Archives of Virology</i> , 1995, 140, 1523-1539.	2.1	54
54	Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. <i>Journal of Clinical Microbiology</i> , 1995, 33, 16-23.	3.9	41

#	ARTICLE	IF	CITATIONS
55	Competitive polymerase chain reaction and analysis of viral activity at the molecular level. <i>Genetic Analysis, Techniques and Applications</i> , 1994, 11, 1-6.	1.5	24
56	Quantitation of hepatitis C virus genome molecules in plasma samples. <i>Journal of Clinical Microbiology</i> , 1994, 32, 1939-1944.	3.9	59
57	Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo. <i>Journal of Virology</i> , 1994, 68, 2495-2502.	3.4	70
58	Trans-Activation of Epidermal Growth Factor Receptor Gene by the Hepatitis B Virus X-Gene Product. <i>Virology</i> , 1993, 196, 878-882.	2.4	68
59	Clearance of HIV-1 viraemia after seroconversion. <i>Lancet, The</i> , 1993, 341, 315-316.	13.7	21
60	Hepatitis B virus preC mutants in human hepatocellular carcinoma tissues. <i>Research in Virology</i> , 1993, 144, 297-301.	0.7	17
61	Sequence analysis of the hepatitis B virus pre-C region in hepatocellular carcinoma [HCC] and nontumoral liver tissues from HCC patients. <i>Virology</i> , 1992, 188, 890-895.	2.4	29
62	Human immunodeficiency virus type 1 and hepatitis B virus transcription in peripheral blood lymphocytes from co-infected subjects. <i>Archives of Virology</i> , 1992, 126, 1-9.	2.1	18
63	Lack of detectable human T-cell lymphotropic virus type I sequences in samples from multiple sclerosis patients. <i>Journal of Medical Virology</i> , 1992, 36, 155-161.	5.0	9
64	Absolute quantitation of viremia in human immunodeficiency virus infection by competitive reverse transcription and polymerase chain reaction. <i>Journal of Clinical Microbiology</i> , 1992, 30, 1752-1757.	3.9	185
65	Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. <i>Journal of Virology</i> , 1992, 66, 7328-7335.	3.4	133
66	A single-step DNA extraction procedure for the detection of serum hepatitis B virus sequences by the polymerase chain reaction. <i>Journal of Virological Methods</i> , 1991, 32, 245-253.	2.1	25
67	Detection of human immunodeficiency virus type 1 transcripts in peripheral blood lymphocytes by the polymerase chain reaction. <i>Journal of Virological Methods</i> , 1991, 32, 31-39.	2.1	24
68	Detection of human immunodeficiency virus type 1 genomic RNA in plasma samples by reverse-transcription polymerase chain reaction. <i>Journal of Medical Virology</i> , 1991, 34, 89-95.	5.0	49
69	Growth-factor independence of a new differentiated hepatitis B virus DNA-negative human hepatoma cell line. <i>Hepatology</i> , 1990, 11, 1024-1032.	7.3	8
70	Expression of high- and low-affinity epidermal growth factor receptors in human hepatoma cell lines. <i>FEBS Letters</i> , 1989, 249, 297-301.	2.8	14
71	Serum-free growth of human hepatoma cells. A review. , 1987, 34, 85-94.		2
72	Differential response of the human hepatoma-derived cell line HA22T/VGH to polypeptide mitogens. <i>FEBS Letters</i> , 1987, 221, 11-17.	2.8	8

#	ARTICLE	IF	CITATIONS
73	Modulation of production of hepatitis B surface antigen by a human hepatoma cell line. Journal of Medical Virology, 1984, 13, 117-123.	5.0	6
74	Complement-fixation test for rotavirus detection: comparison and analysis of different methods to reduce anti-complementary activity of some specimens. Journal of Virological Methods, 1982, 3, 329-335.	2.1	1